Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Committee has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.
In the video below, published by OncLive, watch as SITC Immediate Past President Lisa H. Butterfield, PhD, discusses the SITC Immune Biomarkers Committee.
The SITC Immune Biomarkers Committee reconvened on May 16–17, 2018 for a two-day workshop on critical next steps in the field, including:
A review of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) on Dec. 4, 2018.
Enduring materials from this program are also available to the general public. Please click here to begin accessing the presentations.
Presentations and video recordings are available based on permission from presenters.
NCI/CCR and SITC co-sponsored a 2016 biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in JITC in March 2017. Click here to read Immunotherapy biomarkers 2016: overcoming the barriers. Also, to learn more about the event and its schedule, click here.
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic evaluation of immune regulation and modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force Journal of Translational Medicine, December 2010
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" Journal of Translational Medicine, December 2008
Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients Journal of Immunotherapy, March/April 2005
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy Journal of Immunotherapy, March/April 2002
The following are the currently active subcommittees of the SITC Immune Biomarkers Committee and their purpose:
PURPOSE: The Data Sharing Subcommittee provides expert guidance and insights on the management, analysis, and sharing of biomarker data and resources between diverse organizations in the cancer immunotherapy setting.
PURPOSE: The Microbiome Subcommittee provides expert guidance and insights on best practices and recommendations regarding microbiome research for application in the cancer immunotherapy setting.
PURPOSE: The Resources & Useful Tools Subcommittee provides expert guidance and insights on the latest technologies and resources available, or soon to be available for biomarker identification and validation to advance cancer immunotherapies.
PURPOSE: The Tumor Mutational Burden (TMB) Subcommittee provides expert guidance and recommendations regarding scientific biology, technologies and practices relating to TMB as a quantitative genomic biomarker for personalized medicine in the cancer immunotherapy setting.
Lisa H. Butterfield, PhD PICI Research Center, Parker Institute for Cancer Immunotherapy; University of California, San Francisco
Mary L. Disis, MD University of Washington
Bernard A. Fox, PhD Earle A. Chiles Research Institute
David Kaufman, MD, PhDBill & Melinda Gates Medical Research Institute
Samir N. Khleif, MDGeorgetown University
Raj K. Puri, MD, PhD U.S. Food and Drug Administration
Sara M. Krizan Society for Immunotherapy of Cancer (SITC)
John Alvarez, MD, PhDJanssen Research & Development, LLC
Tony Arulanandam, PhD, DVMNextPoint Therapeutics
Jason D. Barbour, PhDSimpatica Medicine, Inc.
Srabani Bhaumik, PhDRoche
Vincenzo Bronte, MDUniversity of Verona
Marcus O. Butler, MDPrincess Margaret Hospital/Ontario Cancer Institute
Michael A. Cannarile, PhDRoche Pharma Research & Early Development
Alessandra Cesano, MD, PhDNanoString Inc.
Raphael Clynes, MD, PhDXencor, Inc.
Madhav Dhodapkar, MDYale Cancer Center
Kevin K. Dobbin, PhDCollege of Public Health, UGA
Jerome Galon, PhDUniversite Pierre Et Marie Curie, Sorbonne Universites
Sacha Gnjatic, PhDIcahn School of Medicine at Mount Sinai
Bruno GomesRoche Pharma Research and Early Development
Tim F. Greten, MDNational Institutes of Health
Jean-Charles J. B. Grivel, PhDSidra Medical and Research Center
Leif Håkansson, MDUniversity of Lund
Brent A. Hanks, MD, PhDDuke University Medical Center
Alexandre Harari, PhDUniversity Hospital of Lausanne (CHUV)
Priti S. Hegde, PhDGenentech, Inc.
Siwen Hu-Lieskovan, MD, PhDUniversity of California Los Angeles
Sylvia Janetzki, MDZellNet Consulting, Inc
Michael D. Kalos, PhDJanssen Oncology
Vaios Karanikas, PhDRoche Innovation Center Zurich
Mohan Karkada, PhDWyss Institute for Biologically Inspired Engineering at Harvard Univversity
John M. Kirkwood, MDUPMC Hillman Cancer Center
Ilan Kirsch, MDAdaptive Biotechnologies Corp.
Thomas O. Kleen, PhDPrecision for Medicine
Yoshinobu Koguchi, MD, PhDEarle A. Chiles Research Institute, Providence Cancer Center
Beatrix Kotlan, PhDNational Institute of Oncology
Pia Kvistborg, PhDNetherlands Cancer Institute
Dominic W. Lai, MDAbbVie
Peter P. Lee, MDCity of Hope
Amanda W. Lund, PhDOregon Health & Science University
Cristina Maccalli, PhDSidra Medical and Research Department
Holden T. Maecker, PhDStanford University Medical Center
Francesco M. Marincola, MDRefuge Biotechnologies
Giuseppe V. Masucci, MD, PhDKarolinska Institutet
Howard L. McLeod, PharmDMoffitt Cancer Center
Elza Meeusen, PhDCancerProbe Pty Ltd
Aung Naing, MD, FACPUniversity of Texas MD Anderson Cancer Center
Ruslan D. Novosiadly, PhD, MDEli Lilly and Company
Raj K. Puri, MD, PhDFood and Drug Administration
Igor Puzanov, MD, MSCI, FACPRoswell Park Comprehensive Cancer Center
Laura Rosa Brunet, ScDRosa Brunet Consulting LTD
Sergio Rutella, MD, PhD, FRCPathThe John van Geest Cancer Research Centre
Senthamil R. Selvan, PhDBiomarker Strategies, LLC
Janet C. Siebert, MSCytoAnalytics
Tasha Sims, PhDRegeneron Pharmaceuticals, Inc.
Eric A. Singer, MD, MA, FACSRutgers Cancer Institute of New Jersey
Wenru Song, MD, PhDAstraZeneca
Edward C. Stack, PhDJounce Therapeutics
David F. Stroncek, MDNational Institutes of Health
Magdalena Thurin, PhDNational Institutes of Health
Giorgio Trinchieri, MDNational Cancer Institute
Nicholas Tschernia, MDUniversity of Rochester
Theresa L. Whiteside, PhDUniversity of Pittsburgh Cancer Institute
Jon M. Wigginton, MDMacroGenics, Inc.
Timothy L. Wyant, PhDCuris Inc
Jianda Yuan, MD, PhDDirector of Translational Immuno-Oncology Research
Yingdong Zhao, PhDNCI - Biometric Research Branch
Heinz Zwierzina, MDInnsbruck Medical University; Chair of the Cancer Drug Development Forum
View Current Members
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org